Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Intravesical pembrolizumab delivers antitumour activity in NMIBC
A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.
Intravesical pembrolizumab delivers antitumour activity in NMIBC
08 Sep 2022Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.